| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg | |||
| Other Sizes |
| Targets |
The primary targets of EGA are proteins involved in endosomal trafficking pathways. EGA selectively inhibits the transport from early endosomes to late endosomes. By blocking this trafficking step, the compound prevents the entry of various acid-dependent bacterial toxins and viruses into mammalian cells. It also delays the lysosomal targeting and degradation of EGFR. The specific molecular targets of EGA within the endosomal trafficking machinery are not fully defined in the available literature.
|
|---|---|
| ln Vitro |
In vitro, EGA demonstrates selective inhibition of endosomal trafficking pathways. The compound prevents the entry of multiple toxins and viruses into mammalian cells by blocking the transport from early endosomes to late endosomes. EGA also delays lysosomal targeting and degradation of EGFR. The compound's activity is assessed in cell-based assays measuring the uptake of toxins, viruses, or fluorescent tracers. However, detailed IC50 values are not extensively reported.
|
| ln Vivo |
In vivo data for EGA are not extensively reported in the available literature. As a selective inhibitor of endosomal trafficking, the compound has potential for in vivo applications in studying the role of endosomal trafficking in toxin and virus entry, as well as in receptor trafficking and signaling. However, specific in vivo efficacy data, including animal models, dosing regimens, and pharmacokinetic-pharmacodynamic relationships, are not detailed in the available sources.
|
| Enzyme Assay |
In vitro receptor binding assays are not typically performed for EGA, as it targets endosomal trafficking proteins rather than cell surface receptors. The compound's activity is assessed in functional assays measuring endosomal trafficking. For example, cells are treated with EGA, and the trafficking of fluorescent tracers, toxins, or viruses through the endosomal pathway is monitored by fluorescence microscopy or flow cytometry.
|
| Cell Assay |
Cellular assays for EGA are performed in various cell types to assess its effects on endosomal trafficking. Cells are treated with EGA, and the uptake and trafficking of fluorescent tracers, toxins, or viruses are monitored. The compound's ability to inhibit the transport from early endosomes to late endosomes is assessed by measuring the colocalization of tracers with endosomal markers. The compound's effects on EGFR trafficking and degradation are also assessed.
|
| Animal Protocol |
In vivo animal studies with EGA are not extensively documented in the available literature. Based on its inhibition of endosomal trafficking, potential in vivo models could include studies of toxin or virus infection, where EGA would be administered to prevent pathogen entry. However, specific protocols are not detailed in the available sources. The compound is intended for laboratory research use only.
|
| ADME/Pharmacokinetics |
EGA has a molecular weight of 346.22 and a molecular formula of C16H16BrN3O. It is typically dissolved in DMSO for in vitro studies. The compound is stable when stored as a powder at -20°C. However, detailed pharmacokinetic parameters such as absorption, distribution, metabolism, excretion, half-life, and bioavailability are not available in the literature for this research compound.
|
| Toxicity/Toxicokinetics |
Comprehensive toxicology data for EGA are not extensively reported. The compound is classified as a research-use-only chemical and is not intended for human consumption. Specific toxicological data, including acute toxicity, genotoxicity, and target organ effects, are not reported in the available literature.
|
| Additional Infomation |
EGA is a research-grade compound not approved for clinical use. Its primary application is as a pharmacological tool for studying endosomal trafficking pathways. The compound is used to investigate the mechanisms of toxin and virus entry into cells, as well as the role of endosomal trafficking in receptor signaling and degradation. It is also used as a tool to study the trafficking of EGFR and other cell surface receptors.
|
| Molecular Formula |
C16H16N3OBR
|
|---|---|
| Molecular Weight |
346.222
|
| Exact Mass |
345.047
|
| CAS # |
415687-81-9
|
| PubChem CID |
5332392
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Index of Refraction |
1.609
|
| LogP |
5.38
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
21
|
| Complexity |
357
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
N(C1C(=CC=CC=1C)C)C(=O)N/N=C/C1C=CC(Br)=CC=1
|
| InChi Key |
QVNLLEFLGISSAQ-VCHYOVAHSA-N
|
| InChi Code |
InChI=1S/C16H16BrN3O/c1-11-4-3-5-12(2)15(11)19-16(21)20-18-10-13-6-8-14(17)9-7-13/h3-10H,1-2H3,(H2,19,20,21)/b18-10+
|
| Chemical Name |
1-[(E)-(4-bromophenyl)methylideneamino]-3-(2,6-dimethylphenyl)urea
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8883 mL | 14.4417 mL | 28.8834 mL | |
| 5 mM | 0.5777 mL | 2.8883 mL | 5.7767 mL | |
| 10 mM | 0.2888 mL | 1.4442 mL | 2.8883 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT02562976 | COMPLETED | Other: gastric atrophy and intestinal metaplasia | Early Gastric Cancer | Shanghai Jiao Tong University School of Medicine | 2013-05 | |
| NCT05436119 | UNKNOWN STATUS | Dietary Supplement: GrowBaby | Pre-Eclampsia Premature Birth Small for Gestational Age Infant |
GrowBaby Life Project | 2022-07 | |
| NCT05597605 | COMPLETED | Device: The SHINE SYSTEM | Diabetes Mellitus Diabetes Mellitus, Type 1 Diabetes Mellitus, Type 2 Hyperglycaemia (Diabetic) |
Indigo Diabetes NV | 2022-09-21 | Not Applicable |
| NCT02924623 | COMPLETED | Rheumatoid Arthritis | Centre Hospitalier Universitaire de Nīmes | 2016-02-01 | ||
| NCT06550063 | RECRUITING | Esophagus Cancer Gastric Cancer HER2-low Cancer HER2-positive Cancer |
St. James's Hospital, Ireland | 2024-08-20 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
